Literature DB >> 22323718

Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.

Yasuyuki Mitani1, Junko Yarimizu, Kyoko Saita, Hiroshi Uchino, Hiroki Akashiba, Yoshitsugu Shitaka, Keni Ni, Nobuya Matsuoka.   

Abstract

γ-Secretase inhibitors (GSIs) reduce amyloid-β (Aβ) peptides but inevitably increase the β-C-terminal fragment (β-CTF) of amyloid precursor protein (APP), potentially having undesirable effects on synapses. In contrast, γ-secretase modulators (GSMs) reduce Aβ42 without increasing β-CTF. Although the Aβ-lowering effects of these compounds have been extensively studied, little effort has been made to investigate their effects on cognition. Here, we compared the effects of two GSIs--(2S)-2-hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamide (LY450139, semagacestat) and (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxazol-3-yl)phenyl]methyl]amino-5,5,5-trifluoropentanamide (BMS-708163)--and a second-generation GSM [{(2S,4R)-1-[(4R)-1,1,1-trifluoro-7-methyloctan-4-yl]-2-[4-(trifluoromethyl)phenyl]piperidin-4-yl}acetic acid (GSM-2)] on spatial working memory in APP-transgenic (Tg2576) and nontransgenic mice using the Y-maze task. While acute dosing with either GSI ameliorated memory deficits in 5.5-month-old Tg2576 mice, these effects disappeared after 8 d subchronic dosing. Subchronic dosing with either GSI rather impaired normal cognition in 3-month-old Tg2576 mice, with no inhibition on the processing of other γ-secretase substrates, such as Notch, N-cadherin, or EphA4, in the brain. LY450139 also impaired normal cognition in wild-type mice; however, the potency was 10-fold lower than that in Tg2576 mice, indicating an APP-dependent mechanism likely with β-CTF accumulation. Immunofluorescence studies revealed that the β-CTF accumulation was localized in the presynaptic terminals of the hippocampal stratum lucidum and dentate hilus, implying an effect on presynaptic function in the mossy fibers. In contrast, both acute and subchronic dosing with GSM-2 significantly ameliorated memory deficits in Tg2576 mice and did not affect normal cognition in wild-type mice. We demonstrated a clear difference between GSI and GSM in effects on functional consequences, providing new insights into strategies for developing these drugs against Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22323718      PMCID: PMC6621706          DOI: 10.1523/JNEUROSCI.4264-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  81 in total

1.  MH84: A Novel γ-Secretase Modulator/PPARγ Agonist--Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer's Disease.

Authors:  Maximilian Pohland; Stephanie Hagl; Maren Pellowska; Mario Wurglics; Manfred Schubert-Zsilavecz; Gunter P Eckert
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 2.  Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease.

Authors:  Wei Xu; Fang Fang; Jianqing Ding; Chengbiao Wu
Journal:  Traffic       Date:  2018-02-05       Impact factor: 6.215

3.  Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability.

Authors:  Martin Pettersson; Douglas S Johnson; John M Humphrey; Todd W Butler; Christopher W Am Ende; Benjamin A Fish; Michael E Green; Gregory W Kauffman; Patrick B Mullins; Christopher J O'Donnell; Antonia F Stepan; Cory M Stiff; Chakrapani Subramanyam; Tuan P Tran; Beth Cooper Vetelino; Eddie Yang; Longfei Xie; Kelly R Bales; Leslie R Pustilnik; Stefanus J Steyn; Kathleen M Wood; Patrick R Verhoest
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

4.  BMS-708,163 targets presenilin and lacks notch-sparing activity.

Authors:  Christina J Crump; Suita V Castro; Feng Wang; Nikolay Pozdnyakov; T Eric Ballard; Sangram S Sisodia; Kelly R Bales; Douglas S Johnson; Yue-Ming Li
Journal:  Biochemistry       Date:  2012-09-04       Impact factor: 3.162

5.  Ligand-dependent activation of EphA4 signaling regulates the proteolysis of amyloid precursor protein through a Lyn-mediated pathway.

Authors:  Wei-Bin Lai; Bo-Jeng Wang; Ming-Kuan Hu; Wen-Ming Hsu; Guor Mour Her; Yung-Feng Liao
Journal:  Mol Neurobiol       Date:  2013-11-12       Impact factor: 5.590

Review 6.  γ-Secretase inhibitors and modulators: Mechanistic insights into the function and regulation of γ-Secretase.

Authors:  Pengju Nie; Abhishek Vartak; Yue-Ming Li
Journal:  Semin Cell Dev Biol       Date:  2020-04-02       Impact factor: 7.727

7.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.

Authors:  Tatiana Melnikova; DaMin Park; Lauren Becker; Deidre Lee; Eugenia Cho; Nuzhat Sayyida; Jing Tian; Karen Bandeen-Roche; David R Borchelt; Alena V Savonenko
Journal:  Neurobiol Dis       Date:  2016-08-26       Impact factor: 5.996

8.  Alternative Processing of the Amyloid Precursor Protein Family by Rhomboid Protease RHBDL4.

Authors:  Sandra Paschkowsky; Mehdi Hamzé; Felix Oestereich; Lisa Marie Munter
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

Review 9.  Development and mechanism of γ-secretase modulators for Alzheimer's disease.

Authors:  Christina J Crump; Douglas S Johnson; Yue-Ming Li
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162

10.  Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.

Authors:  Tatiana Melnikova; Susan Fromholt; HyunSu Kim; Deidre Lee; Guilian Xu; Ashleigh Price; Brenda D Moore; Todd E Golde; Kevin M Felsenstein; Alena Savonenko; David R Borchelt
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.